Unknown

Dataset Information

0

Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.


ABSTRACT: OBJECTIVE:This report presents tenofovir (TFV) alafenamide (TAF) and elvitegravir (EVG) fabricated into nanoparticles for subcutaneous delivery as prevention strategy. DESIGN:Prospective prevention study in humanized bone marrow-liver-thymus (hu-BLT) mice. METHODS:Using an oil-in-water emulsion solvent evaporation technique, TAF?+?EVG drugs were entrapped together into nanoparticles containing poly(lactic-co-glycolic acid). In-vitro prophylaxis studies (90% inhibition concentration) compared nanoparticles with drugs in solution. Hu-BLT (n?=?5/group) mice were given 200?mg/kg subcutaneous, and vaginally challenged with HIV-1 [5?×?10 tissue culture infectious dose for 50% of cells cultures (TCID50)] 4 and 14 days post-nanoparticle administration (post-nanoparticle injection). Control mice (n?=?5) were challenged at 4 days. Weekly plasma viral load was performed using RT-PCR. Hu-BLT mice were sacrificed and lymph nodes were harvested for HIV-1 viral RNA detection by in-situ hybridization. In parallel, CD34 humanized mice (3/time point) compared TFV and EVG drug levels in vaginal tissues from nanoparticles and solution. TFV and EVG were analyzed from tissue using liquid chromatograph-tandem mass spectrometry (LC-MS/MS). RESULTS:TAF?+?EVG nanoparticles were less than 200?nm in size. In-vitro prophylaxis indicates TAF?+?EVG nanoparticles 90% inhibition concentration was 0.002??g/ml and TAF?+?EVG solution was 0.78??g/ml. TAF?+?EVG nanoparticles demonstrated detectable drugs for 14 days and 72?h for solution, respectively. All hu-BLT control mice became infected within 14 days after HIV-1 challenge. In contrast, hu-BLT mice that received nanoparticles and challenged at 4 days post-nanoparticle injection, 100% were uninfected, and 60% challenged at 14 days post-nanoparticle injection were uninfected (P?=?0.007; Mantel-Cox test). In-situ hybridization confirmed these results. CONCLUSION:This proof-of-concept study demonstrated sustained protection for TAF?+?EVG nanoparticles in a hu-BLT mouse model of HIV vaginal transmission.

SUBMITTER: Mandal S 

PROVIDER: S-EPMC5283613 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.

Mandal Subhra S   Prathipati Pavan K PK   Kang Guobin G   Zhou You Y   Yuan Zhe Z   Fan Wenjin W   Li Qingsheng Q   Destache Christopher J CJ  

AIDS (London, England) 20170201 4


<h4>Objective</h4>This report presents tenofovir (TFV) alafenamide (TAF) and elvitegravir (EVG) fabricated into nanoparticles for subcutaneous delivery as prevention strategy.<h4>Design</h4>Prospective prevention study in humanized bone marrow-liver-thymus (hu-BLT) mice.<h4>Methods</h4>Using an oil-in-water emulsion solvent evaporation technique, TAF + EVG drugs were entrapped together into nanoparticles containing poly(lactic-co-glycolic acid). In-vitro prophylaxis studies (90% inhibition conce  ...[more]

Similar Datasets

| S-EPMC6339842 | biostudies-literature
| S-EPMC7899215 | biostudies-literature
| S-EPMC4879396 | biostudies-literature
| S-EPMC4278848 | biostudies-literature
| S-EPMC7428394 | biostudies-literature
| S-EPMC6667714 | biostudies-literature
| S-EPMC2627483 | biostudies-literature
| S-EPMC5228611 | biostudies-literature
| S-EPMC5172523 | biostudies-literature
| S-EPMC7935460 | biostudies-literature